LM11A 31 is an experimental small-molecule ligand designed to modulate the p75 neurotrophin receptor (p75NTR), a target currently under investigation for its potential in treating neurodegenerative conditions… Read more
LM11A 31 is an experimental small-molecule ligand designed to modulate the p75 neurotrophin receptor (p75NTR), a target currently under investigation for its potential in treating neurodegenerative conditions such as Alzheimer's disease and Huntington's disease. To support the rigorous analytical requirements of pharmaceutical development, this category includes high-quality reference standards, metabolites, and stable isotope labelled compounds. These materials are essential for laboratories engaged in impurity profiling, pharmacokinetic studies, and the validation of analytical methods. By providing well-characterized related compounds and deuterated internal standards, researchers can ensure accurate quantitative analysis and quality control throughout the drug discovery and development process. These compounds enable scientists to identify impurities, track metabolic pathways, and maintain precision in complex analytical testing, ultimately supporting the reliable assessment of therapeutic candidates in clinical and preclinical research environments.